OnKure, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Conditions
- Advanced CancerBreast Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06239467
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸University of California San Diego UCSD, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
- Conditions
- RAS MutationMelanomaNRAS Gene Mutation
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05340621
- Locations
- 🇺🇸
CTCA Phoenix, part of City of Hope, Phoenix, Arizona, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Florida Health Cancer Center, Gainesville, Florida, United States
A Study of OKI-179 in Patients With Solid Tumors
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03931681
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States